Nath Bio-Genes September-quarter profit falls 46% to Rs 2.2697 crore

Nath Bio-Genes (India) Limited reported standalone net profit of Rs 2.2697 crore for the quarter ended 30 September 2026, 46% below Rs 4.2009 crore a year earlier, as finance cost rose to Rs 5.5046 crore from Rs 3.3041 crore. Revenue from operations declined 6% to Rs 37.2673 crore.

Why did Nath Bio-Genes’ September-quarter profit fall?

Nath Bio-Genes’ profit declined because profit before finance cost and exceptional items fell by Rs 1.2925 crore year on year, while finance cost increased by Rs 2.2005 crore. Profit before finance cost and exceptional items was Rs 6.8543 crore in the quarter ended 30 September 2026, compared with Rs 8.1461 crore in the corresponding 2025 quarter.

Finance cost reduced profit after finance cost to Rs 1.3498 crore, from Rs 4.842 crore a year earlier. Nath Bio-Genes then reported exceptional items income of Rs 1.815 crore, which lifted profit before tax to Rs 3.1648 crore, compared with Rs 4.842 crore in the prior-year quarter when no exceptional item was reported.

Current tax expense was Rs 88.51 lakh, up from Rs 64.11 lakh in the September 2025 quarter. Net profit was therefore Rs 2.2697 crore against Rs 4.2009 crore, while total comprehensive income was Rs 2.2822 crore against Rs 4.1134 crore.

How did Nath Bio-Genes’ revenue and costs change?

Nath Bio-Genes reported revenue from operations of Rs 37.2673 crore for the September 2026 quarter, down Rs 2.5034 crore from Rs 39.7707 crore a year earlier. Total expenses declined by Rs 1.3065 crore to Rs 32.253 crore, a smaller reduction than the revenue decrease, and operating profit before other income, finance cost and exceptional items fell to Rs 5.0142 crore from Rs 6.2112 crore.

Production and seed-conditioning expenses increased to Rs 21.3878 crore from Rs 20.5456 crore. Selling and distribution expenses rose to Rs 6.8205 crore from Rs 4.9271 crore, while employee benefit expense declined to Rs 9.4284 crore from Rs 9.6617 crore.

The change in inventories of produced and traded goods was negative Rs 14.9795 crore, compared with negative Rs 7.9498 crore in the corresponding quarter. Purchases of stock-in-trade increased to Rs 1.5494 crore from Rs 27.70 lakh, and other expenses rose to Rs 7.1014 crore from Rs 5.1228 crore.

Other income was Rs 1.8401 crore, compared with Rs 1.9349 crore a year earlier. Adding that income to operating profit produced Rs 6.8543 crore of profit before finance cost and exceptional items, down from Rs 8.1461 crore in the prior-year quarter.

What did Nath Bio-Genes report for the half year?

Nath Bio-Genes reported Rs 360.1101 crore of revenue from operations for the six months ended 30 September 2026, compared with Rs 319.9425 crore for the six months ended 30 September 2025. The half-year revenue increase contrasts with the Rs 2.5034 crore year-on-year decline in the September quarter.

Total expenses for the six-month period were Rs 321.0259 crore, up from Rs 275.8039 crore a year earlier. Profit before other income, finance cost and exceptional items was Rs 39.0842 crore, lower than Rs 44.1386 crore in the comparable six months.

Finance cost for the half year rose to Rs 9.2971 crore from Rs 6.1937 crore, while exceptional items income was Rs 3.0148 crore against Rs 2.0634 crore. Net profit for the six months was Rs 34.9265 crore, compared with Rs 42.4069 crore in the previous-year period.

What was the role of finance cost and exceptional income?

Nath Bio-Genes’ finance cost of Rs 5.5046 crore was the principal movement between profit before finance cost and the Rs 1.3498 crore profit after finance cost in the September 2026 quarter. In the corresponding quarter, Rs 3.3041 crore of finance cost reduced the Rs 8.1461 crore pre-finance-cost profit to Rs 4.842 crore.

The Rs 1.815 crore exceptional items income partly offset the lower post-finance-cost result in the 2026 quarter. Without that reported item, the profit before tax figure would have remained at Rs 1.3498 crore rather than the reported Rs 3.1648 crore.

The filing does not describe the nature of the Rs 1.815 crore exceptional item in its notes. The year-earlier quarter recorded no exceptional items income or expense, so the reported pre-tax comparison includes an item that was absent in the comparable period.

What does Nath Bio-Genes disclose about its business and results review?

Nath Bio-Genes says it has one major product segment, Seed Cultivation, and has therefore not provided segmental reporting. Its Rs 37.2673 crore of September-quarter revenue and Rs 2.2697 crore of net profit cannot be allocated across further business segments from this filing.

The company reported nil investor complaints received during the quarter and nil complaints pending at quarter-end. The financial results were reviewed by the Audit Committee on 13 November 2026 and approved by the Board of Directors on 14 November 2026.

The standalone results are unaudited and were subject to a limited review by Gautam N Associates under Standard on Review Engagements 2410. The reviewer stated on 14 November 2026 that nothing had come to its attention indicating a required disclosure failure or material misstatement, while also stating that it had not performed an audit.

Conclusion

Nath Bio-Genes reported a sharper decline in standalone net profit than in revenue for the quarter ended 30 September 2026: net profit fell 46% to Rs 2.2697 crore while revenue declined 6% to Rs 37.2673 crore. Lower operating profit before other income and a Rs 2.2005 crore increase in finance cost outweighed the benefit of Rs 1.815 crore in exceptional items income.

The filing leaves the nature of the Rs 1.815 crore exceptional item unexplained. The next disclosures to watch are whether Nath Bio-Genes provides that detail and whether finance cost, reported at Rs 5.5046 crore for the September quarter and Rs 9.2971 crore for the six months, changes in subsequent results.